← Product Code [OBO](/submissions/OP/subpart-b%E2%80%94diagnostic-devices/OBO) · K182942
# Canon OCT-A1 (K182942)
_Canon, Inc. · OBO · Jul 24, 2019 · Ophthalmic · SESE_
**Canonical URL:** https://fda.innolitics.com/submissions/OP/subpart-b%E2%80%94diagnostic-devices/OBO/K182942
## Device Facts
- **Applicant:** Canon, Inc.
- **Product Code:** [OBO](/submissions/OP/subpart-b%E2%80%94diagnostic-devices/OBO.md)
- **Decision Date:** Jul 24, 2019
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 886.1570
- **Device Class:** Class 2
- **Review Panel:** Ophthalmic
## Indications for Use
The Canon OCT-A1 is an optical coherence tomography system indicated for the in-vivo imaging and measurement of the retinal nerve fiber layer, and optic disc as a tool and an aid in the diagnosis and management of retinal diseases by a clinician.
## Device Story
Canon OCT-A1 is a computer-controlled, non-invasive ophthalmic imaging system; uses Fourier Domain optical coherence tomography (OCT) and confocal laser scanning (SLO) to capture cross-sectional retinal images; scans eye using low-coherence interferometer to measure tissue reflectivity; quantifies ocular structures including ILM, RNFL, NFL+GCL+IPL, RPE, Bruch's membrane, and full retinal thickness; operated by clinicians in clinical settings; provides high-resolution images and quantitative measurements; aids in diagnosis and management of retinal diseases; benefits patients through non-invasive structural assessment of ocular tissue.
## Clinical Evidence
Prospective, randomized, single-center US study (n=125) comparing Canon OCT-A1 to Optovue RTVue Avanti across normal, glaucoma, and retinal disease populations. Primary endpoints: agreement and precision (repeatability/reproducibility) for full retinal thickness, RNFL, GCC, and ONH parameters. Results showed consistent mean differences (e.g., ~25µm in FRT due to RPE inclusion) and acceptable precision, with Canon OCT-A1 showing lower variability in several GCC and ONH parameters.
## Technological Characteristics
Spectral Domain OCT; 860 nm SLD light source; 70,000 A-scan/s; 20µm (X/Y) and 3.4µm (Z) resolution. SLO imaging (780 nm LD). Materials/specs: AAMI/ANSI ES60601-1, IEC 60601-1-2, IEC 60825-1, ISO 10993, ISO 15004, ANSI Z80.36-2016. Connectivity: Standalone/networked. Software: Moderate level of concern.
## Regulatory Identification
An ophthalmoscope is an AC-powered or battery-powered device containing illumination and viewing optics intended to examine the media (cornea, aqueous, lens, and vitreous) and the retina of the eye.
## Special Controls
*Classification.* Class II (special controls). The device, when it is an AC-powered opthalmoscope, a battery-powered opthalmoscope, or a hand-held ophthalmoscope replacement battery, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 886.9.
## Predicate Devices
- Optovue RTVue XR OCT Avanti with Normative Database ([K153080](/device/K153080.md))
## Submission Summary (Full Text)
> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
July 24, 2019
Canon Inc. % Ryan Bouchard VP, Medical Devices Ora. Inc. 300 Brickstone Square Andover, MA 01810
# Re: K182942
Trade/Device Name: Canon OCT-A1 Regulation Number: 21 CFR 886.1570 Regulation Name: Ophthalmoscope Regulatory Class: Class II Product Code: OBO, HLI Dated: June 17, 2019 Received: June 18, 2019
# Dear Ryan Bouchard:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{1}------------------------------------------------
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801): medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safetyreporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-devicereporting-mdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
for Bradley Cunningham Assistant Director DHT1A: Division of Ophthalmic Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices Office of Product Evaluation and Ouality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
# Indications for Use
510(k) Number (if known) K182942
Device Name Canon OCT-A1
Indications for Use (Describe)
The Canon OCT-A1 is an optical coherence tomography system indicated for the in-vivo imaging and measurement of the retinal nerve fiber layer, and optic disc as a tool and an aid in the diagnosis and management of retinal diseases by a clinician.
| Type of Use (Select one or both, as applicable) |
|-------------------------------------------------|
|-------------------------------------------------|
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
### CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
## 510(k) Summary
This summary of the 510(k) premarket notification for the Canon OCT-A1 K182942 is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
### Owner Company name, address a.
Canon Inc. 9-1, Imaikami-cho Nakahara-ku. Kawasaki Kanagawa 211-8501 Japan
Contact person: Tatsuya Yamazaki
#### b. Contact/Application Correspondent
Ryan Bouchard Ora, Inc. 300 Brickstone Square Andover, MA 01810 Telephone: (978) 332-9574 Facsimile: (978) 689-0020 E-mail: rbouchard@oraclinical.com
### Date Prepared C.
July 24, 2019
#### d. Name of Device
| Trade Name: | Canon OCT-A1 *- |
|----------------------------|-------------------------------|
| Common Names: | Optical Coherence Tomography |
| Classification Name: | Tomography, optical coherence |
| Classification Regulation: | 21 CFR 886.1570 |
| Product Code: | OBO |
| 510(k) Number: | K182942 |
#### Predicate Device e.
Optovue RTVue XR OCT Avanti with Normative Database (K153080)
### f. Device Description
The Canon OCT-A1 *- is an Optical Coherence Tomography (OCT) system intended for use as a non-invasive imaging device for viewing and measuring ocular tissue structures with micrometer range resolution. The OCT-A1 is a computer controlled ophthalmic imaging system. The device scans the patient's eye using a low coherence interferometer to measure the reflectivity of retinal tissue. The cross sectional retinal tissue structure is composed of a sequence of A-scans. It has a traditional patient and instrument interface like most ophthalmic devices.
{4}------------------------------------------------
*: "Al" stands for the "Automatic-1" which means the first Canon OCT with the automatic alignment and adjustment feature.
The OCT-A1 uses Fourier Domain OCT, a method that involves spectral analysis of the returned light rather than mechanic moving parts in the depth scan. Fourier Domain OCT allows scan speeds about 65 times faster than the mechanical limited Time Domain scan speeds.
The OCT-A1 quantifies numerous ocular structures. The various retinal layers or structures, which are imaged or measured, include the following:
1) The internal limiting membrane (ILM) 2) The retinal nerve fiber layer (RNFL) 3) The NFL+GCL+IPL thickness 4) The retinal pigment epithelium (RPE) 5) Bruch's membrane (BM) 6) The full retina thickness
### Indications for Use g.
The Canon OCT-A1 is an optical coherence tomography system indicated for the invivo imaging and measurement of the retina, retinal nerve fiber layer, and optic disc as a tool and an aid in the diagnosis and management of retinal diseases by a clinician.
#### h. Statement of Substantial Equivalence
Canon, Inc. believes that the Canon OCT-A1 described in this notification and for use under the conditions of the proposed labeling is substantially equivalent to a legally marketed predicate device that is a Class II medical device which is the Optovue RTVue XR OCT cleared in K153080.
{5}------------------------------------------------
| Feature | Canon OCT-A1 | RTVue XR OCT (K153080) |
|----------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Manufacturer | Canon Inc. | Optovue, Inc. |
| Classification | 886.1570 | 886.1570 |
| Product Code | OBO | HLI, OBO |
| Indications for use | The Canon OCT-A1 is an optical
coherence tomography system indicated
for the in-vivo imaging and measurement
of the retina, retinal nerve fiber layer, and
optic disc as a tool and an aid in the
diagnosis and management of retinal
diseases by a clinician. | The RTVue XR OCT Avanti with
Normative Database is an optical
coherence tomography system indicated
for the in vivo imaging and measurement
of the retina, retinal nerve fiber layer, and
optic disc as a tool and aid in the
diagnosis and management of retinal
diseases by a clinician.
The RTVue XR OCT Avanti with
Normative Database is also a quantitative
tool for the comparison of retina, retinal
nerve fiber layer, and optic disc
measurements in the human eye to a
database of known normal subjects. It is
intended for use as a diagnostic device to
aid in the detection and management of
ocular diseases.
The RTVue XR OCT Avanti with
AngioVue™ software is indicated as an
aid in the visualization of vascular
structures of the retina and choroid. |
| Technological Characteristics: OCT | | |
| Imaging | Spectral Domain OCT | Spectral Domain OCT |
| Scan Rate | 70,000 A-Scan/s | 70,000 A-Scan/s |
| Light Source | | |
| -Wave Length | 860 nm (SLD) | 840 nm (SLD) |
| -Power Output | 7.5 mW | Unknown |
| -Continuous/Pulsed | Pulsed | Unknown |
| -Pulse Durations | 100μs | Unknown |
| Field of View | Scan width: 3 mm to 10 mm
Scan depth: 2 mm | Scan width: 2 mm to 12 mm
Scan depth: 2 to 3 mm |
| Optical Resolution | 20µm (in the X and Y directions), 3.4 µm
(in the Z direction) | 15µm (in the X and Y directions), 5 µm
(in the Z direction) |
| Exposure Power at
Pupil | 893 μW | ≤750 μW |
| Feature | Canon OCT-A1 | RTVue XR OCT (K153080) |
| Technological Characteristics: SLO | | |
| Imaging | Near IR observation (Confocal laser scanning) | Near IR observation |
| Light Source | | |
| -Wavelength | 780 nm (LD) | 735 nm (LED) |
| -Power Output | 30mW | Unknown |
| -Continuous/Pulsed | Pulsed | Unknown |
| -Pulse Durations | 41ns | Unknown |
| Field of View | 45° x 34° | 32° x 22° |
| Optical Resolution | 25µm (in the X and Y directions) | 25µm (in the X and Y directions) |
| Technological Characteristics: Light for Anterior Segment Adjustment | | |
| Wavelength | 970 nm | Unknown |
| Power output | 5.5mW | Unknown |
| Continuous/Pulsed | Continuous | Unknown |
| Pulse Durations | - | Unknown |
| Technological Characteristics: Internal Fixation Lamp | | |
| Wavelength | 590 nm | Unknown |
| Power output | 2.8mW | Unknown |
| Continuous/Pulsed | Pulsed | Unknown |
| Pulse Durations | 260.ns | Unknown |
| Technological Characteristics: External Fixation Lamp | | |
| Wavelength | 460 nm | Unknown |
| Power output | 2.32 ed | Unknown |
| Continuous/Pulsed | Continuous | Unknown |
| Pulse Durations | - | Unknown |
| Technological Characteristics: Others | | |
| Minimum Pupil Diameter Required | φ 3.0 mm | φ 2.5 mm |
| Focus Range | - 18 D to +15 D | - 15 D to +12 D |
{6}------------------------------------------------
{7}------------------------------------------------
| Feature | Canon OCT-A1 | RTVue XR OCT (K153080) |
|---------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| Measurement and Analysis | | |
| Imaging of the
Fundus | SLO | SLO |
| Retinal Thickness Measurement | | |
| -Total | ILM to RPE | VRI to RPE |
| -Inner | No | VRI to IPL |
| -Outer | No | RPE to IPL |
| GCC Thickness
(NFL+GCL+IPL
Thickness) | Yes | Yes |
| - S - I difference | No | Yes |
| - Focal loss volume | No | Yes |
| - Global loss
volume | No | Yes |
| RNFL Thickness
Measurement | Along the circumference of a circle of
3.45 mm diameter which is targeted
around the ONH | Along the circumference of a circle of
3.45 mm diameter which is targeted
around the ONH |
| Optic Disc Analysis | | |
| -Disc area | Yes | Yes |
| -Rim area | Yes | Yes |
| -Cup area | No | Yes |
| -Cup volume | Yes | Yes |
| -Rim volume | Yes | Yes |
| -Nerve head
volume | No | Yes |
| -C/D area | Yes | Yes |
| -C/D vertical | Yes | Yes |
| -C/D horizontal | Yes | Yes |
| -R/D minimum | Yes | No |
Both the Canon OCT-A1 and the Optovue XR OCT are OCT devices. The principle of operation is identical in that both devices employ a non-invasive, non-contact lowcoherence interferometry technique [specifically, spectral domain optical coherence tomography (SD-OCT)] to generate high-resolution cross-sectional images of internal ocular tissue microstructures by measuring optical reflections from tissue. Both provide cross sectional images of the posterior structures of the eye (i.e., retina, including the ganglion and retinal nerve fiber layers.
There are minor differences in technological characteristics between the Canon OCT-A1 and the predicate device for the OCT including wavelength, size of field of view, optical
{8}------------------------------------------------
resolution, and exposure power at pupil. There are also minor differences in technological characteristics between the Canon OCT-A1 and the predicate device for the SLO including wavelength and field of view. There are also differences related to minimum pupil diameter required for measurement and focus range. Regarding measurement and analysis, the retinal thickness measurement methodology differs between the Canon OCT-A1 and the predicate device. There are also differences in the optic disc analysis.
Performance testing including both bench testing and clinical testing demonstrated substantial equivalence. Therefore, based on the same intended use and similar technological characteristics with substantial equivalence to the predicate device confirmed with performance testing, the Canon OCT-A1 is technologically and functionally equivalent to the predicate device, RTVue XR OCT (K153080). The differences between the proposed device, OCT-A1, and the predicate device are insignificant and do not raise new issues of safety or effectiveness of the device. The Canon OCT-A1 is as safe and effective as its predicate devices, and thus, may be considered substantially equivalent.
#### i. Performance Testing
Canon, Inc. performed bench tests to ensure safety and effectiveness and to demonstrate substantial equivalence of the OCT-A1 to the predicate device. A list of testing conducted included:
- · Scan Speed
- · Transverse and Depth Resolution
- Field of View/Angle of View
- · Scan Depth
- · Testing to the Standards
Electrical Safety: AAMI/ANSI ES60601-1 Electromagnetic Compatibility: IEC 60601-1-2 Safety of Laser Products: IEC 60825-1 Biocompatibility: ISO 10993-1, ISO 10993-5, ISO 10993-10 Ophthalmic Instruments: ISO 15004-1, ISO 15004-2 Optical Radiation Hazard Analysis: ANSI Z80.36-2016.
Software verification and validation testing were conducted and documentation was provided as recommended by FDA's Guidance for Industry and FDA Staff, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices." The software for this device was considered as a "Moderate" level of concern-. The software verification and validation was conducted in two stages, one which included bench testing based on proper recognition of layer and quantitative measurement of thickness or area. The second stage of the software validation was performed by involving human eyes in a clinical evaluation.
Clinical Testing: A clinical study was conducted to demonstrate substantial equivalence of the Canon OCT-A1 (OCT-HS-100) in comparison with Optovue RTVue Avanti. The repeatability and reproducibility were evaluated for the measurements of: Full retinal
{9}------------------------------------------------
thickness: Retinal nerve fiber layer (RNFL) thickness: Ganglion cell complex (GCC) thickness; and Optic nerve head (ONH) The main objective of the clinical study was to assess agreement and precision of the Canon OCT-A1 (OCT-HS-100) in comparison with the Optovue RTVue Avanti. The study was a prospective comparative, randomized, single center study conducted in the US to gather agreement and precision data in at least 99 evaluable eyes, approximately 33 eligible subjects in each of the study subject groups: normal subjects; subjects with glaucoma; and subjects with retinal disease.
The primary inclusion criteria for all groups included: Male or female subjects from 18 vears of age or older who have full legal capacity to volunteer on the date the informed consent is signed; Subjects who can follow the instructions by the clinical staff at the clinical site, and can attend examinations on the scheduled examination date; Subjects who agree to participate in the study
In addition each of the groups had inclusion criteria associated with the specific group.
Normal Group:
- . Subjects with normal eye examinations (without pathology) in one or both eyes on the date of the study visit as observed with a +90 Diopter Fundus Lens;
- Subjects with current best-spectacle-corrected visual acuity (BSCVA) of 20/40 or . better in the normal eye(s)
Glaucoma Group:
- . Subjects who have been diagnosed with glaucoma in the glaucoma study eye(s)
- with a current BSCVA of 20/40 or better in the glaucoma study eve(s) ●
- . History of visual field defects within the previous two (2) months from the study visit or measured on the day of the study visit that is consistent with glaucomatous optic nerve damage
Retinal Disease Group:
- Subjects with a current BSCVA of 20/400 or better in the retinal disease study eve(s) . at the study visit
- Subjects diagnosed with retinal pathology including but not limited to: Non . Exudative Macular Degeneration (dry AMD), Diabetic Macular Edema, Macular Hole, Epiretinal Membrane, Cystoid Macular Edema, or other retinal disease in the study eye(s) as confirmed within the past six (6) months, who exhibit structural lesions in the study eye
- Subjects diagnosed with retinal pathology including but not limited to: Neovascular . Macular Degeneration (wet AMD), Diabetic Retinopathy, Retinal Artery Occlusion, Retinal Vein Occlusion or other retinal disease in the study eye(s) as confirmed within the past six (6) months, who exhibit vascular and/or ischemic lesions in the study eye.
The exclusion criteria was similar for all groups and included:
- Subjects unable to tolerate ophthalmic imaging;
- Subjects with ocular media not sufficiently clear to obtain acceptable OCT images; .
- . Subjects with a history of leukemia, dementia or multiple sclerosis.
{10}------------------------------------------------
- . Subject has a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study
Group specific exclusion criteria included:
- . Normal Group: Subjects with any current ocular pathology other than cataract in the normal eye(s), as determined by self-report and/or investigator assessment at the studv visit:
- . Retinal Disease Group: Subjects with glaucoma in the retinal disease study eye(s), as determined by self-report and/or investigator assessment at the study visit
Three Canon OCT-A1 devices and 3 Optovue RTVue Avanti devices were used. Each Canon OCT-A1 device was paired with 1 of the Optovue RTVue Avanti devices. One device operator was assigned to each device pair to create 3 distinct operator/device configurations. Device operators and investigators were masked to the automated results of segmentation.
This study included 125 subjects with 37 in the normal group, 37 in the glaucoma group, and 38 in the retinal disease group. The study included two main analyses: 1) analysis of agreement and 2) analysis of precision.
In the effectiveness population, the mean (SD) age was 39.1 (15.28) years for the normal eve subjects. 71.6 (8.78) years for the glaucoma eve subjects. 62.1 (15.11) years for the retinal disease eye subjects, 53.5 (17.38) years for the FFA normal eye subjects, and 59.3 (14.73) years FFA retinal disease eve subjects. The overall mean age of all subjects was 57.5 (18.67) years. Sixty-one females and 64 males participated (48.8% and 51.2%, respectively), and the majority of subjects were white 92 (73.6%) and not Hispanic or Latino 101 (80.8%).
# Analysis of Agreement Summary
# Full Retinal Thickness (FRT)
The normal population showed Canon Macula 3D scans tended to have higher FRTs by about 10 to 30 um depending on the parameter with mean differences ranging from 12.56 to 29.95 um.
The glaucoma population showed Canon Macula 3D scans tended to have higher FRTs by about 15 to 30 um depending on the parameter with mean differences ranging from 15.42 to 29.39 um.
The retinal disease population showed Canon Macula 3D scans tended to have higher FRTs by about 15 to 25 um depending on the parameter with mean differences ranging from 12.52 to 24.46 um.
See Table 1 for the mean differences and 95% Limits of Agreement (LOA). Some of the 95% LOAs were fairly wide, as seen in Table 1.
{11}------------------------------------------------
The differences shown between the Canon and the Optovue devices are largely because the two devices use different bands in the RPE as the outer of the retina. Optovue uses the 2nd hyper reflective band (upper border of RPE) as an outer border of the retina and the Canon uses the 3th hyper reflective band (lower border of RPE) as an outer border of the retina. In addition, the diameter of the outer section of the grid for the Canon OCT-A1 is 6mm whereas the Optovue uses a 5mm diameter.
FRT is summarized in Table 1.
| Subject Population
Comparable
Parameter | Canon OCT-A1
Mean (SD) | Optovue
Avanti
RTVue
Mean (SD) | Mean
Difference
(SD) | 95% CI for Mean
Difference | 95% LOA
for
Differences |
|-----------------------------------------------|---------------------------|-----------------------------------------|----------------------------|-------------------------------|-------------------------------|
| All Configurations | | | | | |
| Normal – N | 37 | 37 | | | |
| Central (µm) | 267.20 (19.396) | 248.89 (18.222) | 18.32 (5.056) | (16.69, 19.95) | (8.20, 28.43) |
| Para Inferior (µm) | 339.95 (15.682) | 310.00 (16.159) | 29.95 (6.066) | (28.00, 31.91) | (17.82, 42.09) |
| Para Nasal (µm) | 344.05 (17.430) | 315.30 (18.034) | 28.75 (7.179) | (26.44, 31.06) | (14.39, 43.11) |
| Para Superior (µm) | 343.27 (18.369) | 314.62 (18.160) | 28.65 (7.468) | (26.25, 31.06) | (13.72, 43.59) |
| Para Temporal (µm) | 329.85 (16.339) | 301.92 (16.948) | 27.93 (6.769) | (25.75, 30.11) | (14.39, 41.47) |
| Peri Inferior (µm) | 285.94 (13.608) | 273.38 (13.303) | 12.56 (7.029) | (10.30, 14.83) | (-1.49, 26.62) |
| Peri Nasal (µm) | 314.45 (18.170) | 296.76 (16.744) | 17.69 (6.606) | (15.56, 19.82) | (4.48, 30.90) |
| Peri Superior (µm)…
---
**Source:** [https://fda.innolitics.com/submissions/OP/subpart-b%E2%80%94diagnostic-devices/OBO/K182942](https://fda.innolitics.com/submissions/OP/subpart-b%E2%80%94diagnostic-devices/OBO/K182942)
**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).
**Cite:** Innolitics at https://innolitics.com